An official website of the United States government
Home
Name
Locametz
Alternate Names
Gallium Ga 68 gozetotide
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
Do not Code as treatment. This agent is a radioactive diagnostic agent.
March 22, 2022 FDA approved Locametz (gallium Ga 68 gozetotide), a radioactive diagnostic agent for positron emission tomography of PSMA-positive lesions, including selection of patients with metastatic prostate cancer for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated. Locametz is the first radioactive diagnostic agent approved for patient selection in the use of a radioligand therapeutic agent
March 22, 2022 FDA approved Locametz (gallium Ga 68 gozetotide), a radioactive diagnostic agent for positron emission tomography of PSMA-positive lesions, including selection of patients with metastatic prostate cancer for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated. Locametz is the first radioactive diagnostic agent approved for patient selection in the use of a radioligand therapeutic agent
Coding
This drug should NOT be coded
